Skip to main content
OpenTrials
Completed

NCT Number: NCT01983605

Left Atrial Appendage Exclusion Study

Evaluate the safety and effectiveness of the LARIAT Suture Delivery device in excluding the left atrial appendage in 100 patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jagiellonian University (John Paul II) Hospital

Krakow, Poland

About this study

The objective of this study is to evaluate the safety and effectiveness of the SentreHEART suture delivery system for the exclusion of the left atrial appendage in up to 100 treated patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is greater than or equal to 18 years of age
  • Subject has atrial fibrillation (paroxysmal or persistent)
  • Subject is poor candidate for Warfarin (contraindicated, labile INR, non-compliant)
  • Subject is willing and able to provide written informed consent
  • Subject has a life expectancy of at least 1 year
  • Subject is willing and able to return for scheduled follow up visits

Exclusion criteria

  • Previous cardiac surgery
  • Thrombus in the left atrial appendage or left atrium
  • NYHA Class IV heart failure symptoms
  • Need for emergent cardiac surgery (i.e. cardiogenic shock)
  • LAA is not appropriate for exclusion based upon intraoperative evaluations
  • Current diagnosis of active systemic infection
  • Renal failure requiring dialysis or hepatic failure
  • A known drug and/or alcohol addiction
  • Mental impairment or other conditions, which may not allow subject to understand the nature, significance and scope of the study
  • Pregnancy or desire to get pregnant within 12 months of the study treatment
  • Preoperative need for an intra-aortic balloon pump or intravenous inotropes
  • Patients who have been treated with thoracic radiation
  • Patients in current chemotherapy
  • Patients on long-term treatment with steroids not including intermittent use of inhaled steroids for respiratory diseases.
  • Patients with known connective tissue disorders, i.e. Lupus
  • Previous history of pericarditis
  • Presence of a PFO/ASD or valve implant

Treatment and study plan

LARIAT Suture Delivery Device

Device

LAA exclusion procedure

Primary outcomes

  1. Rate of device related serious adverse events

    Time frame: 30 days

  2. Percent of patients with complete exclusion of the LAA measured with TEE

    Time frame: 90 days

Sponsors and collaborators

Lead sponsor

AtriCure, Inc.

Industry

Registry information

Official study title

Left Atrial Appendage Exclusion Study II

Acronym: PLACE II

Important dates

Study start
2009
Primary completion
2011
Study completion
2013
First posted
Nov 14, 2013
Registry last updated
Jan 9, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.